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Abstract
Background: Difficult-to-treat infections caused by rapidly growing mycobacteria (RGM) are increasingly observed
in clinical settings. However, studies on antimicrobial susceptibilities and effective treatments against RGM in Japan
are limited.
Methods: We conducted susceptibility testing of potential antimicrobial agents, including tigecycline and
tebipenem, against RGM. Clinical RGM isolates were collected from a university hospital in Japan between
December 2010 and August 2013. They were identified using matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry and the sequencing of 16S rRNA, rpoB, and hsp65 genes. The samples were utilized for
susceptibility testing using 16 antimicrobials, with frozen broth microdilution panels.
Results: Forty-two isolates were obtained: 13, Mycobacterium abscessus complex; 12, Mycobacterium chelonae; 9,
Mycobacterium fortuitum; and 8, M. fortuitum group species other than M. fortuitum. Different antimicrobial
susceptibility patterns were observed between RGM species. Clarithromycin-susceptible strain rates were
determined to be 0, 62, and 100% for M. fortuitum, M. abscessus complex, and M. chelonae, respectively. M.
abscessus complex (100%) and >80%M. chelonae isolates were non-susceptible, while 100%M. fortuitum group
isolates were susceptible to moxifloxacin. Linezolid showed good activity against 77%M. abscessus complex,
89%M. fortuitum, and 100%M. chelonae isolates. Regardless of species, all tested isolates were inhibited by
tigecycline at very low minimal inhibitory concentrations (MICs) of ≤0.5 μg/mL. MICs of tebipenem, an oral
carbapenem, were ≤4 μg/mL against all M. fortuitum group isolates.
Conclusions: Our study demonstrates the importance of correct identification and antimicrobial susceptibility
testing, including the testing of potential new agents, in the management of RGM infections.
Keywords: Rapidly growing mycobacteria, Mycobacterium abscessus complex, Antimicrobial susceptibility,
Tigecycline, Tebipenem, Macrolides
Background
Rapidly growing mycobacteria (RGM) can cause various
diseases in humans, including lung, skin and soft tissue,
bone, and catheter-related blood stream infections, as well
as disseminated infections. Mycobacterium abscessus com-
plex, Mycobacterium chelonae, and Mycobacterium fortui-
tum complex are the most commonly encountered RGM
strains clinically. Different strains belonging to the M.
fortuitum group and Mycobacterium smegmatis and
Mycobacterium mucogenicum group strains, which can
cause human infections, account for <10% of rapidly
growing mycobacterial infections [1, 2].
Recently, M. abscessus complex was divided into three
subspecies, M. abscessus subsp. abscessus, M. abscessus
subsp. bolletii, and M. abscessus subsp. massiliense,
based on the multiple sequencing analyses of 16S rRNA
and several housekeeping genes, such as rpoB, hsp65,
secA, and sodA. M. abscessus subsp. abscessus and M.
abscessus subsp. bolletii usually possess an inducible
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macrolide resistant gene, unlike M. abscessus subsp.
massiliense [3]. M. fortuitum group comprises of more
than 10 species, including M. fortuitum, Mycobacterium
peregrinum, Mycobacterium senegalense, Mycobacterium
septicum, Mycobacterium alvei, Mycobacterium hous-
tonense, Mycobacterium boenickei, Mycobacterium
conceptionense, Mycobacterium porcinum, Mycobac-
terium neworleansense, Mycobacterium brisbanense,
and Mycobacterium mageritense, although some con-
troversy about the classification of M. mageritense
still exists [4, 5].
Difficult-to-treat infections caused by RGM are increas-
ingly observed in clinical settings, especially by M. abscessus
complex, which is considered one of the most resistant
strains [3]. Additionally, inducible macrolide resistance, a
recently recognized phenomenon, may restrict the thera-
peutic role of macrolides. This resistance may be related to
the insufficient efficacy of clarithromycin-based treatment
of M. abscessus subsp. abscessus infection, even when a par-
ticular isolate is initially shown to be sensitive to the drug
[6, 7]. To date, only a small amount of data is available on
antimicrobial susceptibilities of RGM isolated in Japan. Sus-
ceptibility of RGM to some antimicrobials can be tested in
a limited number of reference laboratories, while an accur-
ate identification of RGM at the species level is difficult for
most of the clinical laboratories, resulting in limited suscep-
tibility data as well.
The development of novel treatment options is neces-
sary since the effective antimicrobial treatment options
against RGM, in particular against M. abscessus subsp.
abscessus, are limited [3]. Oral medications need to be
investigated in addition to parenteral agents, since the
long-term antimicrobial treatments are often required.
Tigecycline, the first clinically available glycylcycline, has
broad activity against multidrug-resistant bacteria, due
to its low sensitivity to major mechanisms of tetracycline
resistance [8]. Minimal inhibitory concentrations (MICs)
of this drug were shown to be low against rapidly grow-
ing mycobacterial isolates tested throughout the world
[9–14]. Tebipenem, a novel oral carbapenem that is ap-
proved for use in Japan, was recently showed to have po-
tent in vitro activity against Mycobacterium tuberculosis
[15], although the data are still not complete.
The purpose of this study was to examine the suscepti-
bilities of RGM clinical isolates collected in Japan to 16
antimicrobial agents, including potential new agents,
such as tigecycline and tebipenem. We placed particular
emphasis on the correct identification of isolates at the
species level, prior to the drug susceptibility testing.
Methods
Bacterial identification
Between December 2010 and August 2013, 71 strains of
RGM were isolated from various clinical samples at the
University of Tokyo Hospital, Japan. We identified these
strains using matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) and
the sequencing of three conserved genes (16S rRNA,
rpoB, and hsp65). The MALDI Biotyper system and the
Mycobacterium Library 1.0 database (Bruker Daltonics
K.K., Kanagawa, Japan) were used for MALDI-TOF MS
analyses.
Antimicrobial susceptibility testing
Susceptibility testing was performed according to Clinical
and Laboratory Standards Institute (CLSI) guidelines M24-
A2 [16], using frozen broth microdilution panels. The final
drug concentration ranges were as follows: 4 to 128 μg/mL
of amikacin, 1 to 16 μg/mL of tobramycin, 0.12 to 16 μg/
mL of tigecycline, 0.25 to 16 μg/mL of minocycline, 0.25 to
8 μg/mL of ciprofloxacin, 0.25 to 8 μg/mL of moxifloxacin,
0.25 to 32 μg/mL of clarithromycin, 1 to 16 μg/mL of azi-
thromycin, 2 to 64 μg/mL of linezolid, 1 to 64 μg/mL of
imipenem, 1 to 64 μg/mL of meropenem, 0.25 to 2 μg/mL
of faropenem, 0.5 to 4 μg/mL of tebipenem, 4 to 128 μg/
mL of cefmetazole, 2 to 64 μg/mL of cefepime, and 1/19 to
8/152 μg/mL of trimethoprim/sulfamethoxazole. Tigecyc-
line was purchased from Selleckchem (Houston, TX, USA).
Frozen broth microdilution panels containing antimicrobial
agents in 100 μL of cation-supplemented Muellar-Hinton
broth were custom-fabricated by Eiken Chemical Co., Ltd.
(Tokyo, Japan). According to the CLSI guidelines [16], the
inoculum was prepared so that the final concentrations
were 1 × 105 to 5 × 105 CFU/mL. Strains were incubated at
37 °C. If microbial growth in the control sample was suffi-
cient, MICs were measured at day 3. Otherwise, the incuba-
tion period was prolonged, and MICs were measured at
day 4 or 5. For clarithromycin, MIC measurements were
performed at day 3 and day 14 to detect inducible macro-
lide resistance. In this study, clarithromycin MICs were de-
termined at day 14 of incubation. M. fortuitum ATCC 6841
was used as a quality control reference strain.
The MIC breakpoints, indicating susceptible, intermedi-
ate, and resistant strains, were interpreted according to
the CLSI criteria for amikacin, tobramycin, minocycline,
ciprofloxacin, moxifloxacin, clarithromycin, linezolid, imi-
penem, meropenem, and trimethoprim/sulfamethoxazole
[16]. To date, there are no consensus breakpoints for tige-
cycline, azithromycin, faropenem, tebipenem, cefmetazole,
and cefepime. Because of this, a modified susceptibility
breakpoint of ≤4 μg/mL for tigecycline proposed by Pet-
rini [17] was used in this study (Table 1).
Results
Bacterial isolates and species identification
Among the investigated strains, 46 were identified as M.
abscessus complex, M. chelonae, and M. fortuitum group
(including M. fortuitum, M. mageritense, M. peregrinum,
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M. porcinum, and M. septicum). Despite the sequen-
cing of housekeeping genes (rpoB and hsp65) and
the use of MALDI-TOF MS, we were unable to dis-
tinguish between M. abscessus subsp. abscessus and
M. abscessus subsp. bolletii correctly. Therefore, we
have described isolates belonging to M. abscessus
species as M. abscessus complex. Of these three clin-
ically important species/groups of RGM (46 isolates),
four isolates were excluded: we were not able to cul-
tivate three of them for susceptibility testing and the
results of MALDI-TOF MS and gene sequencing
were disparate for one isolate. Therefore, we in-
cluded a total of 42 isolates in this study. They were
collected from sputum/respiratory specimens (n =
35), wounds (n = 3), blood (n = 1), ascites (n = 1),
lymph node aspirate (n = 1), and ocular discharge
sample (n = 1).
Among the 42 isolates included in this study, 13 iso-
lates were identified as M. abscessus complex, 12 as M.
chelonae, nine as M. fortuitum, four as M. mageritense,
two as M. peregrinum, one as M. porcinum, and one as
M. septicum.
Antimicrobial susceptibility
In this study, sufficient microbial growth in the
growth control samples was observed after 72 h of in-
cubation. The results of the susceptibility testing
(MIC range, MIC50, MIC90, and percentage of suscep-
tibility) to 16 antimicrobial agents are presented in
Table 2. All isolates (n = 42) were highly susceptible
to tigecycline, with MIC50 values of ≤0.12 μg/mL,
MIC90 value of 0.25 μg/mL, and MIC range of ≤0.12–
0.5 μg/mL.
Antimicrobial susceptibility patterns of RGM
M. abscessus complex
All isolates belonging to M. abscessus complex (n =
13) were susceptible to amikacin. However, they
were all resistant to tobramycin and trimethoprim-
sulfamethoxazole and not susceptible to fluoroquino-
lones (both moxifloxacin and ciprofloxacin). Seventy
percent of the isolates and none of them were sus-
ceptible to imipenem and meropenem, respectively.
Around two-thirds of the isolates were susceptible to
clarithromycin and linezolid (Table 2).
M. chelonae
Among M. chelonae strains (n = 12), all isolates were
susceptible to clarithromycin and linezolid, azithromycin
MICs were shown to be ≤2 μg/mL for all isolates. The
majority of M. chelonae isolates were susceptible to ami-
noglycosides: 83% were susceptible to tobramycin, used
predominantly in the treatment of M. chelonae infec-
tions [16]. All M. chelonae isolates were resistant to
minocycline, while they were susceptible to another
tetracycline derivative, tigecycline. Susceptibility to dif-
ferent carbapenems was diverse, with 58% of isolates
susceptible to imipenem and only 8% susceptible to mer-
openem (Table 2).
M. fortuitum
Similar to M. abscessus complex, among M. fortuitum
strains (n = 9), all isolates were susceptible to amikacin
and resistant to tobramycin. Many antimicrobial agents
showed activity or had low MICs in vitro against M. for-
tuitum. All M. fortuitum isolates were susceptible to
fluoroquinolones (ciprofloxacin and moxifloxacin), and
around two-thirds of isolates were susceptible to imipe-
nem and meropenem. Furthermore, the MIC90 values of
tebipenem and cefmetazole against M. fortuitum isolates
were lower compared with the values against M. absces-
sus complex and M. chelonae. All isolates were found to
be susceptible to tigecycline, although 44% were resistant
to minocycline. However, all M. fortuitum isolates were
not susceptible to clarithromycin and had high MICs
(>16 μg/mL) to azithromycin (Table 2).
Other M. fortuitum group
Other M. fortuitum group isolates, M. mageritense (n =
4), M. peregrinum (n = 2), M. porcinum (n = 1), and M.
septicum (n = 1), generally had good sensitivity to fluoro-
quinolones, carbapenems (including tebipenem), cefme-
tazole, and linezolid; however, only a small number of
these strains had been included in this study. Addition-
ally, similar to M. fortuitum, all these isolates, except M.
peregrinum, showed poor sensitivity to clarithromycin.
M. fortuitum group isolates were not susceptible to




MICa (μg/mL) for category
Susceptible Intermediate Resistant
Amikacin ≤16 32 ≥64
Tobramycin ≤2 4 ≥8
Tigecycline ≤4 >4
Minocycline ≤1 2–4 ≥8
Ciprofloxacin ≤1 2 ≥4
Moxifloxacin ≤1 2 ≥4
Clarithromycin ≤2 4 ≥8
Linezolid ≤8 16 ≥32
Imipenem ≤4 8–16 ≥32
Meropenem ≤4 8–16 ≥32
Sulfamethoxazole ≤38 ≥76
Abbreviation MIC minimal inhibitory concentration
aBreakpoints of each drug, except for tigecycline, are based on the Clinical and
Laboratory Standards Institute recommendations. Breakpoints for tigecycline
were based on those proposed by Petrini [17]
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MIC (μg/mL) Percentage of isolates
Range MIC50 MIC90 S I R
M. abscessus complex (13)
Amikacin 8–16 16 16 100 0 0
Tobramycin 8– >16 16 >16 0 0 100
Tigecycline ≤0.12–0.5 0.25 0.5 100 -a 0
Minocycline ≤0.25– >16 >16 >16 15.4 15.4 69.2
Ciprofloxacin 4– >8 >8 >8 0 0 100
Moxifloxacin 2– >8 8 >8 0 7.7 92.3
Clarithromycin ≤0.25– >32 0.5 >32 61.5 7.7 30.8
Azithromycin ≤1– >16 16 >16 - - -
Linezolid ≤2–32 4 16 76.9 15.4 7.7
Imipenem 2–16 8 16 30.8 69.2 0
Meropenem 8–64 16 32 0 69.2 30.8
Faropenem >2 >2 >2 - - -
Tebipenem 4– >4 >4 >4 - - -
Cefmetazole 8–64 32 32 - - -
Cefepime 32– >64 64 >64 - - -
Sulfamethoxazole >152 >152 >152 0 - 100
M. chelonae (12)
Amikacin ≤4–64 16 16 91.7 0 8.3
Tobramycin ≤1–4 2 4 83.3 16.7 0
Tigecycline ≤0.12–0.25 ≤0.12 0.25 100 - 0
Minocycline 8– > 16 16 >16 0 0 100
Ciprofloxacin ≤0.25– >8 8 >8 16.7 8.3 75.0
Moxifloxacin ≤0.25–8 2 4 16.7 41.7 41.7
Clarithromycin ≤0.25 ≤0.25 ≤0.25 100 0 0
Azithromycin ≤1–2 ≤1 2 - - -
Linezolid ≤2–8 ≤2 8 100 0 0
Imipenem ≤1–16 4 8 58.3 41.7 0
Meropenem ≤1–64 64 64 8.3 8.3 83.3
Faropenem ≤0.25– >2 >2 >2 - - -
Tebipenem ≤0.5– >4 >4 >4 - - -
Cefmetazole ≤4– >128 >128 >128 - - -
Cefepime ≤2–64 16 32 - - -
Sulfamethoxazole 38– >152 >152 >152 8.3 - 91.7
M. fortuitum (9)
Amikacin ≤4 ≤4 ≤4 100 0 0
Tobramycin 16– >16 >16 >16 0 0 100
Tigecycline ≤0.12 ≤0.12 ≤0.12 100 - 0
Minocycline ≤0.25– >16 ≤0.25 >16 55.6 0 44.4
Ciprofloxacin ≤0.25 ≤0.25 ≤0.25 100 0 0
Moxifloxacin ≤0.25 ≤0.25 ≤0.25 100 0 0
Clarithromycin 4– >32 32 >32 0 11.1 88.9
Table 2 Results of susceptibility testing of 16 antimicrobial
agents against RGM (Continued)
Azithromycin >16 >16 >16 - - -
Linezolid 4–16 8 16 88.9 11.1 0
Imipenem ≤1–8 2 8 66.7 33.3 0
Meropenem 4–8 4 8 66.7 33.3 0
Faropenem >2 >2 >2 - - -
Tebipenem 1–4 2 4 - - -
Cefmetazole 8–16 16 16 - - -
Cefepime >64 >64 >64 - - -
Sulfamethoxazole 76– >152 >152 >152 0 - 100
M. mageritense (4)
Amikacin ≤4– >128 128 >128 25.0 0 75.0
Tobramycin >16 >16 >16 0 0 100
Tigecycline ≤0.12 ≤0.12 ≤0.12 100 - 0
Minocycline 2– >16 2 >16 0 50.0 50.0
Ciprofloxacin ≤0.25–1 ≤0.25 1 100 0 0
Moxifloxacin ≤0.25 ≤0.25 ≤0.25 100 0 0
Clarithromycin 32– >32 >32 >32 0 0 100
Azithromycin 16– >16 16 >16 - - -
Linezolid ≤2–16 ≤2 16 75.0 25.0 0
Imipenem ≤1–2 ≤1 2 100 0 0
Meropenem ≤1–4 ≤1 4 100 0 0
Faropenem 2– >2 2 >2 - - -
Tebipenem 1–4 2 4 - - -
Cefmetazole ≤4–8 ≤4 8 - - -
Cefepime >64 >64 >64 - - -
Sulfamethoxazole ≤19– >152 152 >152 25.0 - 75.0
M. peregrinum (2)
Amikacin ≤4 ≤4 ≤4 100 0 0
Tobramycin 4–8 4 8 0 50.0 50.0
Tigecycline ≤0.12 ≤0.12 ≤0.12 100 - 0
Minocycline >16 >16 >16 0 0 100
Ciprofloxacin ≤0.25 ≤0.25 ≤0.25 100 0 0
Moxifloxacin ≤0.25 ≤0.25 ≤0.25 100 0 0
Clarithromycin ≤0.25 ≤0.25 ≤0.25 100 0 0
Azithromycin ≤1– >16 ≤1 >16 - - -
Linezolid 4–8 4 8 100 0 0
Imipenem ≤1–2 ≤1 2 100 0 0
Meropenem 2–4 2 4 100 0 0
Faropenem >2 >2 >2 - - -
Tebipenem ≤0.5–1 ≤0.5 1 - - -
Cefmetazole ≤4–8 ≤4 8 - - -
Cefepime >64 >64 >64 - - -
Sulfamethoxazole 38– >152 38 >152 50.0 - 50.0
Abbreviations RGM rapidly growing mycobacteria, MIC minimal
inhibitory concentration, S susceptible, I intermediate, R resistant
anot applicable
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minocycline, while they all were susceptible to tigecyc-
line (Table 2).
Discussion
In this study, conducted in Japan, antimicrobial suscepti-
bility patterns of different species of RGM were found to
vary. However, rapidly growing mycobacterial strains, re-
gardless of species, showed good sensitivity to tigecyc-
line. Although a susceptibility breakpoint of ≤4 μg/mL
was used for tigecycline [17] in this study, the growth of
all isolates was inhibited by tigecycline at very low MICs,
that is, ≤0.5 μg/mL. To date, most of the RGM world-
wide remain sensitive to tigecycline in vitro. The MIC
values of tigecycline against a total of 122 rapidly grow-
ing mycobacterial isolates (including 50 tetracycline-
resistant isolates) collected in USA [9], 40 isolates
obtained in Taiwan [10], 25 isolates collected in Turkey
[11], 160 isolates in Taiwan [12], and 57 isolates ob-
tained in Korea [13] were ≤4 μg/mL. The MIC ranges in
the first four studies were reported to be ≤0.06–1 μg/
mL, 0.064–2 μg/mL, 0.12–1 μg/mL, and 0.0625–4 μg/
mL, respectively; the MIC range was not reported in the
Korean study. However, in a recent study conducted in
China, it was shown that tigecycline MIC values against
two or three of 73 RGM isolates were somewhat high,
with an MIC of 8 μg/mL [14].
It was previously reported that tigecycline may have a
promising role in the treatment of multi-drug resistant
RGM infections, not only in vitro but also in vivo. A
study following 52 patients with M. abscessus and M.
chelonae infections, where prior therapy attempts had
failed, showed that tigecycline-containing regimens ad-
ministered for ≥1 month resulted in clinical improve-
ment in more than 60% of the patients [18]. However,
both CLSI and European Committee on Antimicrobial
Susceptibility Testing (EUCAST) have not defined
tigecycline MIC breakpoints for RGM yet. Additionally,
tigecycline has not been approved for the treatment of
mycobacterial infections, demonstrating a need for fur-
ther clinical studies and appropriate approvals, in order
to develop new treatment options.
Macrolides are one of the most important drugs used for
the treatment of RGM. However, we observed that a
relatively large number of isolates showed resistance to
macrolides, with important differences in susceptibility pat-
terns among species; the obtained rates of clarithromycin-
susceptible strains were 0, 62, and 100% of M. fortuitum,
M. abscessus complex, and M. chelonae, respectively.
Additionally, M. mageritense strain, which comprises 10%
of all isolates in this study, shows intrinsic resistance to
macrolides [2]. Inducible resistance to macrolides can occur
during the application of macrolide-containing regimen
during the treatment of infections caused by several RGM
species. The erythromycin ribosome methyltransferase
genes, erm(38) and erm(41), have been reported to confer
inducible macrolide resistance to M. fortuitum and M.
abscessus subsp. abscessus, respectively [6, 19], while
erm(41) is absent from M. chelonae [6]. Inducible resistance
may be at least partially responsible for the difficulties ob-
served during the treatment of M. abscessus infections [20].
Previously, approximately 80% of M. fortuitum sam-
ples were shown to be susceptible to clarithromycin
[19], which was not observed in this study. In a study
conducted in Spain, of 89M. fortuitum clinical isolates,
75 (84.3%) were shown to harbor the erm gene, while 42
(47.2%) were not susceptible to clarithromycin [21]. Re-
gional differences in clarithromycin susceptibility and
the prevalence of erm gene in the clinical isolates of M.
fortuitum may exist. Further studies investigating this
issue are necessary.
Azithromycin susceptibility breakpoint is not defined
by the CLSI and EUCAST, and CLSI lists clarithromycin
as a class representative of a new generation of macro-
lides, which includes azithromycin, for the RGM suscep-
tibility testing [16]. However, to date, no conclusive
results about the equivalence of the clinical effects of
clarithromycin and azithromycin therapies in the pa-
tients with M. abscessus infections were obtained. In the
experimental models of M. abscessus subsp. abscessus
and M. abscessus subsp. massiliense infections, clarithro-
mycin induced erm(41) expression, leading to a higher
induction of macrolide resistance compared with the ef-
fects of azithromycin on M. abscessus subsp. abscessus.
As a result, clarithromycin was shown to have a lower
effect against M. abscessus subsp. abscessus in vitro and
in vivo compared with azithromycin, while both of these
macrolides showed comparable effects against M. absces-
sus subsp. massiliense infections [7]. In order to ensure
the efficient treatment using macrolides, a correct
identification of subspecies of M. abscessus complex (in-
cluding M. abscessus subsp. abscessus and M. abscessus
subsp. massiliense) is clinically important, although we
have not performed this identification, as it is technically
cumbersome.
Carbapenem is one of the available treatment options
for RGM infections. Imipenem was demonstrated to be
more efficient against M. abscessus complex, M. chelo-
nae, and M. fortuitum than meropenem in this study. In
Japan, faropenem (an oral penem) and tebipenem (an
oral carbapenem) are approved for clinical use. Tebipe-
nem MIC values were shown to be ≤4 μg/mL against all
isolates belonging to M. fortuitum group (including M.
fortuitum, M. mageritense, M. peregrinum, M. porcinum,
and M. septicum) in this study, while the MICs of this
compound against the majority of M. abscessus complex
and M. chelonae isolates were >4 μg/mL (Table 2). Since
concentrations higher than 4 μg/mL are achievable in
human serum at therapeutic doses [15], tebipenem may
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represent an orally available drug of choice for the treat-
ment of infections caused by M. fortuitum group strains.
Further clinical studies are necessary to evaluate these
new agents against difficult-to-treat RGM infections.
Many RGM strains, with the exception of M. mageri-
tense, showed sensitivity to amikacin. Tobramycin was
active only against M. chelonae and M. septicum. CLSI
discourages clinical use of tobramycin for the treatment
of infections caused by M. abscessus or M. fortuitum
group. As the information on M. mageritense suscepti-
bility to amikacin remains limited, it should be further
investigated.
In this study, we used M. fortuitum ATCC 6841 as a
control strain, which represents one of the potential lim-
itations of this study, as the current CLSI-recommended
quality control strain is M. peregrinum ATCC 700686.
Conclusions
We performed susceptibility testing of 16 antimicrobial
agents against 42 isolates of M. abscessus complex, M.
chelonae, and M. fortuitum group collected in Japan,
which were correctly identified using MALDI-TOF MS
and 16S rRNA, rpoB, and hsp65 gene sequencing.
Tigecycline was able to inhibit the growth of all tested
isolates at very low MICs of ≤0.5 μg/mL, regardless of
species and tetracycline resistance. Tebipenem showed
MIC values of ≤4 μg/mL against all isolates of M.
fortuitum group. We have showed that the patterns of
antimicrobial susceptibility clearly differ among RGM
species, and that the correct identification of RGM spe-
cies (and even subspecies) and antimicrobial susceptibil-
ity testing, including the identification of novel agents,
are important for the treatment of RGM infections.
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